Bio-Rad Reports 2 Percent Lift in Q2 Sales | GenomeWeb

NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market on Tuesday a 2 percent increase in second quarter revenues despite essentially flat sales for its Life Science segment.

For the quarter ended June 30, the Hercules, Calif.-based firm reported revenues of $536.8 million compared to $525.3 million in Q2 2013 and falling short of the consensus analyst estimate of $537.6 million.

On a currency-neutral basis, quarterly revenues increased 1 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.